Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose 50 g/l;  ; potassium chloride 1.49 g/l; sodium chloride 4.5 g/l;   - solution for infusion - active: glucose 50 g/l   potassium chloride 1.49 g/l sodium chloride 4.5 g/l   excipient: water for injection - potassium chloride, glucose and sodium chloride intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the medicine is compatible with this solution.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose 50 g/l;  ; potassium chloride 1.49 g/l; sodium chloride 9 g/l;   - solution for infusion - active: glucose 50 g/l   potassium chloride 1.49 g/l sodium chloride 9 g/l   excipient: water for injection - potassium chloride, glucose and sodium chloride intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the medicine is compatible with this solution.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - levothyroxine sodium, quantity: 112 microgram - tablet - excipient ingredients: purified talc; maize starch; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose - eltroxin is indicated for the management of demonstrated thyroid hormone deficiency.,eltroxin is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - levothyroxine sodium, quantity: 137 microgram - tablet - excipient ingredients: colloidal anhydrous silica; purified talc; microcrystalline cellulose; magnesium stearate; maize starch - eltroxin is indicated for the management of demonstrated thyroid hormone deficiency.,eltroxin is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - levothyroxine sodium, quantity: 175 microgram - tablet - excipient ingredients: magnesium stearate; maize starch; colloidal anhydrous silica; purified talc; microcrystalline cellulose - eltroxin is indicated for the management of demonstrated thyroid hormone deficiency.,eltroxin is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - levothyroxine sodium, quantity: 88 microgram - tablet - excipient ingredients: colloidal anhydrous silica; maize starch; magnesium stearate; purified talc; microcrystalline cellulose - eltroxin is indicated for the management of demonstrated thyroid hormone deficiency.,eltroxin is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - levothyroxine sodium, quantity: 150 microgram - tablet - excipient ingredients: purified talc; maize starch; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose - eltroxin is indicated for the management of demonstrated thyroid hormone deficiency.,eltroxin is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Kanada - Inggris - Health Canada

carolina medical products company - sodium polystyrene sulfonate - suspension - 15g - sodium polystyrene sulfonate 15g - potassium-removing agents

Kanada - Inggris - Health Canada

omega laboratories limited - sodium polystyrene sulfonate - powder for solution - 100% - sodium polystyrene sulfonate 100% - potassium-removing agents

Amerika Serikat - Inggris - NLM (National Library of Medicine)

kvk-tech, inc. - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 1 g in 1 g - sodium polystyrene sulfonate is indicated for the treatment of hyperkalemia. limitation of use : sodium polystyrene sulfonate should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)]. sodium polystyrene sulfonate is contraindicated in patients with the following conditions: • hypersensitivity to polystyrene sulfonate resins • obstructive bowel disease • neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the practical exchange ratio of 1 meq potassium per 1 gram of resin. in neonates, sodium polystyrene sulfonate should not be given by the oral route. in both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with sodium polystyrene sulfonate use [see warnings and precautions (5.4)] .